Idelalisib (CAL-101, GS-1101)

目录号:S2226

Idelalisib (CAL-101, GS-1101) Chemical Structure

Molecular Weight(MW): 415.42

Idelalisib (CAL-101, GS-1101) 是选择性p110δ抑制剂,在无细胞试验中IC50为 2.5 nM;对 p110δ 表现出的选择性是对 p110α/β/γ 的 40 到 300 倍,对p110δ的选择性是对 C2β,hVPS34,DNA-PK 和 mTOR的400到4000倍。

规格 价格 库存 购买数量  
RMB 1279.19 现货
RMB 972.85 现货
RMB 3867.24 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献31篇:

客户使用该产品的5个实验数据:

  • Invasive migration of RA FLS was analyzed through growth factor–reduced Matrigel-coated transwell inserts in the presence or absence of 1 µM INK007, 5 µM CAL-101, or 0.3 µM IPI-145, or 0.3 µM GDC-0941 inhibitors or DMSO. Cells were allowed to invade through Matrigel toward PDGF-BB (25 ng/ml) containing media for 24 h and were fixed and stained with Hemacolor staining kit.

    J Immunol, 2014, 192(5): 2063-70 . Idelalisib (CAL-101, GS-1101) purchased from Selleck.

    Ppp2r1afl/fl BCR-ABL1 B-ALL cells transduced with 4-OHT-inducible Cre-ERT2 (Cre) or ERT2-vector (EV) were treated with 4-OHT for 3 days and cell lysates were studied by phospho-protein array analysis. Ppp2r1afl/fl BCR-ABL1 ALL cells were transduced with 4-OHT-inducible Cre or EV control and incubated in the presence of the small molecule signaling inhibitor idelalisib (32 μmol/L; C). Percentages of GFP+ cells were measured by flow cytometry at the times indicated following 4-OHT-treatment. Data are shown as mean ± standard deviation (SD) and representative of at least three independent experiments.

    Cell, 2018, 173(2):470-484. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

  • 293T cells were transfected with HA-tagged Fbxo45. At 48 h after transfection, cells were treated with AKT inhibitor (CAL-101; 10 uM, 4 h), cell extracts from the cytoplasm or nuclei were subjected to IP with anti-HA resin followed by western blot analysis with indicated antibodies.

    Cell Death Differ 2014 21(10), 1535-45. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

    Isoform-selective PI3K inhibitors blocked PI3K signaling in corresponding Rh30-Myr-p110 cells. Rh30-Myr-p110s cells were cultured in serum-free medium for 12 h, and then exposed to CAL-101 at indicated concentrations for additional 1 h. The cells were collected to detect the level of phosphorylated and total Akt. β-Actin was served as loading control.

    Acta Pharmacol Sin 2013 34(9),1201-7. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

  • After starved in serum-free medium for 24 h,A549 cells incubated with the indicated concentrations of CAL-101 for 3 h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 Idelalisib (CAL-101, GS-1101) 是选择性p110δ抑制剂,在无细胞试验中IC50为 2.5 nM;对 p110δ 表现出的选择性是对 p110α/β/γ 的 40 到 300 倍,对p110δ的选择性是对 C2β,hVPS34,DNA-PK 和 mTOR的400到4000倍。
特性 Calistoga 暗示 CAL-101治疗血液恶性肿瘤可能有更广泛的应用价值。
靶点
p110δ [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
2.5 nM 89 nM
体外研究

CAL-101 对p110α, p110β,和p110γ作用效果不大。CAL-101作用于原代嗜碱细胞特定阻断FcϵR1 p110δ调节的 CD63表达,EC50 为8 nM。与急性髓性白血病(AML) 和骨髓增生性肿瘤(MPN) 细胞相比,CAL-101 作用于B-cell急性淋巴细胞白血病(B-ALL)和慢性淋巴细胞白血病(CLL) 细胞时显示更强的活性。CAL-101 作用于SU-DHL-5, KARPAS-422 和CCRF-SB细胞,降低pAktS473, pAktT308, 和下游靶点S6, EC50为0.1到1.0 μM。 [1] CAL-101 作用于CLL细胞,诱导选择性细胞毒性,不是通过突变状态或间期细胞遗传学,主要通过caspase依赖机制。与正常B细胞相比,CAL-101作用于CLL 细胞优先产生细胞毒性,和LY294002相比,作用于其他造血细胞不会产生毒性。CAL-101 作用于T 细胞和天然杀伤细胞 缺乏直接的细胞毒性潜能。CAL-101抑制炎症细胞因子的产生,比如 IL-6, IL-10, TNF-α,和IFN-γ,且激活诱导的细胞因子,如CD40L。CAL-101 也抗CD40L调节的CLL细胞存活。[2] CAL-101 作用于L1236和L591细胞, 诱导细胞在G1期积累,在S期下降,说明 CAL-101可以作为治疗霍杰金淋巴瘤(HL)的一种新策略。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MEC1 M4f3[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGiybVlFVVOR M1X3PWlEPTB;MkCuOEDPxE1? NILWOVAzPTl7OUO1Ni=>
CLL PBMCs M2PJT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\ESG1UVw>? MWXJR|UxRTJwOTDuUS=> NFq3SW0zPTlzN{K2Oy=>
U266 Mn7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVH2XIk1PDBizszN MV[0PEBp MXG3PU42LSCrbnjpZol1cW:wIILheIU> NHPDU4YzPTN|OUOzNi=>
K562 MYnGeY5kfGmxbjDBd5NigQ>? MVSxJO69VQ>? M1XnVVMhcA>? MnrZTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:w MWqyOVAyPDd5NR?=
K562 NFq4[opHfW6ldHnvckBCe3OjeR?= Mnq5NUDPxE1? MkO1N{Bp NY\v[4s5UW6qaXLpeIlwdiCxZjDQO|BUPkticHjvd5Bpd3K7bHH0bY9v M1fLN|I2ODF2N{e1
K562 NVvFVFFSTnWwY4Tpc44hSXO|YYm= MVyxJO69VQ>? MljtN{Bp MXjJcohq[mm2aX;uJI9nKEeVS{OgdIhwe3Cqb4L5cIF1cW:w M2qyflI2ODF2N{e1
K562 NXTRR3IzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWKxJO69VQ>? M3jEdFczKGh? MlHPTY5pcWKrdHnvckBw\iCycn;sbYZmemG2aX;u NVHa[ZBSOjVyMUS3O|U>
Primary AML cell MmHiSpVv[3Srb36gRZN{[Xl? MlvRNUDPxE1? NEDwcms{KGh? MmPxTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:w MX6yOVAyPDd5NR?=
Primary AML cell MkX6SpVv[3Srb36gRZN{[Xl? NXTqW4U6OSEQvF2= MUizJIg> NV65U|ZqUW6qaXLpeIlwdiCxZjDQO|BUPkticHjvd5Bpd3K7bHH0bY9v M4\OU|I2ODF2N{e1
Primary AML cell NFfEcGRHfW6ldHnvckBCe3OjeR?= NXfVTZVrOSEQvF2= MV6zJIg> NH[2U4FKdmirYnn0bY9vKG:oIFfTT|MheGixc4Doc5J6dGG2aX;u NGK3[o0zPTBzNEe3OS=>
Primary AML cell MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXkN3MyKM7:TR?= MoPPN{Bp NXn5SGhjW3WycILld5Nqd25ib3[gdnJPSSC|eX70bIV{cXN? MUKyOVAyPDd5NR?=
Microglia MVHGeY5kfGmxbjDBd5NigQ>? M2H3R|Uh|ryP M3fMT|ExKGh? MVnEUXNQ MUjE[YNz\WG|ZTDv[kBVVk[jIIPlZ5JmfGmxbjDmdo9uKEySUz3zeIlufWyjdHXkJEBxOTFyzsTEPVExSS:GOUGwRUBucWO{b3fsbYE> M2ny[VI1PjJ3Nki0
Primary CLL cell NGPtUllHfW6ldHnvckBCe3OjeR?= MXKxJO69VQ>? Mln4NVUhdWmw MmH5SG1UVw>? MmHKRoxw[2u|IFLDVk1qdmS3Y3XkJGxEWDFic3XybY5mNTViYXP0bZZifGmxbh?= M3HObFI1ODB7MkOz
JEKO-1 MWXGeY5kfGmxbjDBd5NigQ>? NH7jTJUyKM7:TR?= M1XRNFczKGh? MUfJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25iaX6gTYdONXO2aX31cIF1\WRiSlXLU{0y Ml\yNlM{PDF3NEG=
Granta-519 MkLZSpVv[3Srb36gRZN{[Xl? NFT6cW4yKM7:TR?= M3fHPFIhcA>? NHPIR29KdmirYnn0bY9vKG:oIFHreEh1OzB6KTDwbI9{eGixconsZZRqd25? NV25cpdyOjN|NEG1OFE>
Granta-519 NGfETXRHfW6ldHnvckBCe3OjeR?= Mn7vNUDPxE1? MYqyJIg> Mm\GTY5pcWKrdHnvckBw\iCDa4Sod|Q4OylicHjvd5Bpd3K7bHH0bY9v NE\TPVYzOzN2MUW0NS=>
JEKO-1 NU\mc3p4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\RNVAh|ryP MXu3NkBp M3G0[2lvcGmkaYTpc44hd2ZicILvcIln\XKjdHnvckB{dGmpaITsfS=> NFnIOoMzOzN2MUW0NS=>
JEKO-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHn1RZQ2KM7:TR?= MVG3NkBp M3z2eYRw\XNibn;0JIlv\HWlZTDj[YxtKGO7Y3zlJIFzemW|dDDvdkBieG:ydH;zbZM> NH7QO4YzOzZ5NkKyNC=>
MAVER-1 NWjBRZVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fWcFUh|ryP MkPZO|IhcA>? M2rOToRw\XNibn;0JIlv\HWlZTDj[YxtKGO7Y3zlJIFzemW|dDDvdkBieG:ydH;zbZM> MnLkNlM3PzZ{MkC=
MINO MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DQXVUh|ryP M3XqXVczKGh? NX7XNYJY\G:nczDuc5QhcW6mdXPlJINmdGxiY4njcIUh[XK{ZYP0JI9zKGGyb4D0c5Nqew>? MX[yN|Y4PjJ{MB?=
SP53 M1riZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUGwMlEh|ryP NUW0fVVvPzJiaB?= NIfHbYNld2W|IH7veEBqdmS3Y3WgZ4VtdCCleXPs[UBienKnc4Sgc5Ih[XCxcITvd4l{ MYWyN|Y4PjJ{MB?=
HH M3;zW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvHNlAyOCEQvF2= MU[3NkBp MknaSG1UVw>? MoPtTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyC|bHnnbJRtgQ>? M2ricVIzQDBzOUW5
Myla NVHCS2ZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVr3XmE1OTBizszN MnT0O|IhcA>? NXrtTnIyTE2VTx?= NHLucodld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nz NGDYN2YzOjhyMUm1PS=>
SR786 MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTtNVAh|ryP NE\ycXA4OiCq MY\EUXNQ MVfkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m| NIrpbnozOjhyMUm1PS=>
HuT78 M1P6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzrbGwyOCEQvF2= NW\3XWxjPzJiaB?= MkXSSG1UVw>? Mm\w[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?= M13oNlIzQDBzOUW5
MJ MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmX4NVAh|ryP NFjKPWo4OiCq MonXSG1UVw>? MmPL[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?= M1vVVlIzQDBzOUW5
DERL7 MorGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTxNVAh|ryP MUe3NkBp MUDEUXNQ MoXP[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?= NELSXHAzOjhyMUm1PS=>
L1236 NYLrUmlETnWwY4Tpc44hSXO|YYm= NW[5XohnOTBizszN Mnf1NkBp MWfJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25? MWWyNlIyODh5Nx?=
L428 NFz0OGtHfW6ldHnvckBCe3OjeR?= MWexNEDPxE1? M1rmWFIhcA>? NEXIbWtKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36= Mm\hNlIzOTB6N{e=
L591 M2rhOmZ2dmO2aX;uJGF{e2G7 NWTlPW5HOTBizszN MlzoNkBp NGHNRWhKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36= M33j[lIzOjFyOEe3
KMH-2 Ml3hSpVv[3Srb36gRZN{[Xl? NWTNcYI1OTBizszN Ml\YNkBp NWHpcpQyUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;u NYrkUYdoOjJ{MUC4O|c>
L1236 NF7qTJRHfW6ldHnvckBCe3OjeR?= M{DGNlUh|ryP NUDCNJhNOjRiaB?= NGjZRZBDdG:la4Ogd4VkemW2aX;uJI9nKHSqZTDDR2w2 NEO5NJUzOjJzMEi3Oy=>
L591 MlPXSpVv[3Srb36gRZN{[Xl? M3HMXlUh|ryP MYeyOEBp MYDCcI9kc3Nic3XjdoV1cW:wIH;mJJRp\SCFQ1y1 MljPNlIzOTB6N{e=
L1236 Mki4RZBweHSxc3nzJGF{e2G7 NV7ISG5yPSEQvF2= MW[yOEBp NYe2dFljUW6mdXP0bY9vKG:oIHHwc5B1d3Orcx?= MWmyNlIyODh5Nx?=
L591 MWLBdI9xfG:|aYOgRZN{[Xl? MlHlOUDPxE1? M3nES|I1KGh? Ml3VTY5lfWO2aX;uJI9nKGGyb4D0c5Nqew>? NEnRVnQzOjJzMEi3Oy=>
U-87MG MUHGeY5kfGmxbjDBd5NigQ>? NV:zOoJUOTByIH7N M2DuflI1KGh? NYnuO4RWTE2VTx?= NFW5OlJKdmirYnn0bY9vKG:oIDDj[YxtKG2rZ4LheIlwdg>? MmDTNlIxPzl4MEm=
SW1783 MUfGeY5kfGmxbjDBd5NigQ>? NVHRUVh[OTByIH7N MYGyOEBp MWrEUXNQ M1nMbWlvcGmkaYTpc44hd2ZiIHPlcIwhdWmpcnH0bY9v NHizSnAzOjB5OU[wPS=>
U-87MG MmLISpVv[3Srb36gRZN{[Xl? M2n0O|Uh|ryP MXuyOEBp MkfoSG1UVw>? MWjJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25ic4Xid5RidnSrYXzsfS=> MnK1NlIxPzl4MEm=
SW1783 NXXOeIRVTnWwY4Tpc44hSXO|YYm= M3zYdVUh|ryP M4mzRlI1KGh? MVXEUXNQ NULMOplnUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;uJJN2[nO2YX70bYFtdHl? NX\hZ5dPOjJyN{m2NFk>
U-373MG M4DLNGZ2dmO2aX;uJGF{e2G7 NIr5[2Y2KM7:TR?= M362[lI1KGh? NF3Jb3FFVVOR NIXt[4xKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36gd5Vje3SjboTpZYxtgQ>? NWrnSXVCOjJyN{m2NFk>
SK-MG3 MlrzSpVv[3Srb36gRZN{[Xl? NV:xNpJpPSEQvF2= M1XHSVI1KGh? M{XFT2ROW09? MnrOTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIIP1ZpN1[W62aXHscJk> M1PMWFIzODd7NkC5
SU-DHL-5 M2HGZWZ2dmO2aX;uJGF{e2G7 NGD3dpcyKM7:TR?= MYeyOEBp NHHic21FVVOR NE\IOG5KdmS3Y4Tpc44hd2ZiYYDvdJRwe2m| NGm5W|AzODl3OU[wOi=>
WSU-NHL M2m4WGZ2dmO2aX;uJGF{e2G7 MXuxJO69VQ>? MnTyNlQhcA>? NVG2ZpU5TE2VTx?= M2\jPGlv\HWldHnvckBw\iCjcH;weI9{cXN? NH;kWYkzODl3OU[wOi=>
CCRF-SB MWjGeY5kfGmxbjDBd5NigQ>? MY[xJO69VQ>? M3rCVFI1KGh? M1Lj[2ROW09? NIHEO5FKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m| MU[yNFk2QTZyNh?=
INA-6 NXXiZ4RkTnWwY4Tpc44hSXO|YYm= NFnEcG42KM7:TR?= NVzueI9iPiCq MnjmTY5pcWKrdHnvckBw\iCSSUPLM2FsfCCjbnSgSXJMKHCjdHj3ZZk> NEizZ|EzODVyNUG1PC=>
LB MoPJSpVv[3Srb36gRZN{[Xl? MV[1JO69VQ>? MXu2JIg> M122e2lvcGmkaYTpc44hd2ZiUFm0T{9Cc3RiYX7kJGVTUyCyYYToe4F6 M1XwU|IxPTB3MUW4

... Click to View More Cell Line Experimental Data

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[2]
+ 展开

PI3K实验:

用全CLL和正常B细胞溶解物进行PI3K实验。 进行PI3K ELISA 实验。全细胞抽提物加到PI(4,5)P2 底物和反应 buffer(包含 ATP)的混合物中,在室温下温育。加入 PI(3,4,5)P3 探测器和 EDTA混合,反应终止,在室温下温育1小时。混合物转移到PI3K ELISA板上,再温育1小时。 冲洗反应板,然后和第二探测器再温育30分钟。再次冲洗反应板, 加入3,3′,5,5′-四甲基联苯胺溶液 ,反应5分钟,加入H2SO4 终止反应。在450纳米处读数。
细胞实验:[2]
+ 展开
  • Cell lines: CLL B 细胞或健康志愿者的T细胞或NK细胞
  • Concentrations: 0.01-100 μM
  • Incubation Time: 48小时
  • Method: 进行MTT实验测定细胞毒性。1×105个细胞和CAL-101一起温育。加入MTT试剂, 再次温育20小时,然后用溶于PBS的硫酸鱼精蛋白冲洗。加入DMSO, 用分光光度计在540纳米处测定吸光度。使用膜联蛋白/PI液式细胞计检查在不同时间点测定细胞存活力,分析数据。每个样本至少计数104个细胞。以全部阳性细胞与未处理细胞之比百分数的形式来表示实验结果。加入100 μM Z-VAD检测caspase-依赖的细胞凋亡。加入 1 μg/mL CD40L, 800 U/mL IL-4, 50 ng/mL BAFF, 20 ng/mL TNF-α测定存活信号, 或者共培养在纤连蛋白或 HS-5 细胞系基质包被的板上。 基质共培养 在75cm2培养瓶 (80%-100% 融合率) 培养24 小时,然后加入CLL细胞。
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 83 mg/mL warmed (199.79 mM)
Ethanol 23 mg/mL (55.36 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
30% PEG 400 (dissolve first)+0.5% Tween 80+5% Propylene glycol
30mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 415.42
化学式

C22H18FN7O

CAS号 870281-82-6
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03576443 Recruiting Diffuse Large B Cell Lymphoma Nordic Lymphoma Group July 7 2017 Phase 2
NCT02962401 Active not recruiting Waldenstrom Macroglobulinemia French Innovative Leukemia Organisation March 7 2017 Phase 2
NCT02044822 Terminated B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion Gilead Sciences August 6 2014 Phase 2
NCT02436135 Completed Myelofibrosis Gilead Sciences June 5 2015 Phase 1
NCT01980888 Terminated Chronic Lymphocytic Leukemia Gilead Sciences February 5 2014 Phase 3
NCT02739360 Completed Lymphoid Malignancies Gilead Sciences May 4 2016 Phase 4

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    What is the recommended dose of CAL-101 and the route of administration for mouse studies?

  • 回答:

    According to the following paper, S2226 can be used by I.V. administration at the concentration of 40 mg/kg. https://www.ncbi.nlm.nih.gov/pubmed/24625684

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

Tags: 购买Idelalisib (CAL-101, GS-1101) | Idelalisib (CAL-101, GS-1101)供应商 | 采购Idelalisib (CAL-101, GS-1101) | Idelalisib (CAL-101, GS-1101)价格 | Idelalisib (CAL-101, GS-1101)生产 | 订购Idelalisib (CAL-101, GS-1101) | Idelalisib (CAL-101, GS-1101)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID